<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937768</url>
  </required_header>
  <id_info>
    <org_study_id>MC0852</org_study_id>
    <secondary_id>NCI-2009-01147</secondary_id>
    <secondary_id>08-001519</secondary_id>
    <secondary_id>MC0852</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT00937768</nct_id>
  </id_info>
  <brief_title>Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy</brief_title>
  <official_title>Phase II Trial of Temporary Androgen Deprivation Therapy in High Risk Prostate Cancer Following Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies the side effects and how well giving leuprolide
      acetate or goserelin acetate works compared to observation in treating patients with
      high-risk prostate cancer who have undergone radical prostatectomy. Androgens can cause the
      growth of prostate cancer cells. Antihormone therapy, such as goserelin acetate and
      leuprolide acetate, may lessen the amount of androgens made by the body and thus control
      prostate cancer growth. Many times, after surgery, the tumor may not need more treatment
      until it progresses. In this case, observation may be sufficient. However, in some prostate
      cancers there is a chance that tumors can re-grow despite surgery based on certain high risk
      features.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare the difference in the biochemical progression-free survival rate (bPFS) at
      2-years between immediate androgen deprivation therapy (ADT) for nine months in high risk
      prostate cancer patients following radical prostatectomy and a similar high risk patient
      population followed without initiation of immediate ADT treatment.

      SECONDARY OBJECTIVES:

      I. To determine the difference in bPFS, prostate cancer specific survival, and overall
      survival between immediate ADT for nine months and observation for high risk prostate cancer
      patients following radical prostatectomy.

      II. To evaluate the toxicity profile and quality of life (QOL) measured by Functional
      Assessment of Cancer Therapy-Prostate (FACT-P) and linear analogue self assessment (LASA)
      between two treatment arms.

      TERTIARY OBJECTIVES:

      I. To explore if serum and urine biomarker(s) levels at study entry, 9 months, or 24 months
      in the two treatment arms are correlated with biochemical progression-free survival rate.

      II. To explore if &gt; 5 circulating tumor cells (CTCs) or circulating endothelial cells (CECs)
      following study treatments are associated with biochemical progression-free survival rate.

      III. To explore the prognostic and predictive value of tissue based biomarkers in high risk
      prostate cancer patients.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM A: Patients receive leuprolide acetate intramuscularly (IM) on day 1 OR goserelin acetate
      subcutaneously (SC) on day 1. Courses repeat every 3 months for 9 months in the absence of
      disease progression or unacceptable toxicity.

      ARM B: Patients undergo observation every 3 months for 9 months.

      After completion of study treatment, patients are followed up every three months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical Progression-free Survival Rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical Progression-free Survival (BPFS), Overall Survival (OS), and Prostate Cancer Specific Survival (PCS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as Per NCI CTCAE Version 3</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Assessed by the FACT-P and LASA Tool Within and Between the Two Treatment Arms</measure>
    <time_frame>Baseline and months 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of Serum and Urine Biomarkers, and Comparison Between the Two Arms</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Circulating Tumor Cells or Circulating Endothelial Cells Following Study Treatments With Biochemical Progression-free Survival Rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Prognostic and Predictive Tissue Based Biomarkers (CTCs, CECs)</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Stage IIA Prostate Cancer</condition>
  <condition>Stage IIB Prostate Cancer</condition>
  <condition>Stage III Prostate Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (antihormone therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive leuprolide acetate IM on day 1 OR goserelin acetate SC on day 1. Courses repeat every 3 months for 9 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (no antihormone therapy)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergo observation every 3 months for 9 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin Acetate</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm A (antihormone therapy)</arm_group_label>
    <other_name>ZDX</other_name>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (antihormone therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm A (antihormone therapy)</arm_group_label>
    <other_name>A-43818</other_name>
    <other_name>Abbott 43818</other_name>
    <other_name>Abbott-43818</other_name>
    <other_name>Carcinil</other_name>
    <other_name>Depo-Eligard</other_name>
    <other_name>Eligard</other_name>
    <other_name>Enanton</other_name>
    <other_name>Enantone</other_name>
    <other_name>Enantone-Gyn</other_name>
    <other_name>Ginecrin</other_name>
    <other_name>LEUP</other_name>
    <other_name>Leuplin</other_name>
    <other_name>Leuprorelin Acetate</other_name>
    <other_name>Lucrin</other_name>
    <other_name>Lucrin Depot</other_name>
    <other_name>Lupron</other_name>
    <other_name>Lupron Depot</other_name>
    <other_name>Lupron Depot-3 Month</other_name>
    <other_name>Lupron Depot-4 Month</other_name>
    <other_name>Lupron Depot-Ped</other_name>
    <other_name>Procren</other_name>
    <other_name>Procrin</other_name>
    <other_name>Prostap</other_name>
    <other_name>TAP-144</other_name>
    <other_name>Trenantone</other_name>
    <other_name>Uno-Enantone</other_name>
    <other_name>Viadur</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A (antihormone therapy)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PRE-REGISTRATION:

          -  Informed consent explained and signed prior to any study related procedures

          -  Patients with any one of the following &quot;high risk&quot; criteria:

               -  Clinical or pathological Gleason score 8-10

               -  Prostate-specific antigen (PSA) &gt; 20 ng/ml at initial presentation prior to
                  radical prostatectomy

          -  Willingness to provide mandatory tissue for research purposes

          -  Willingness to provide mandatory blood for research purposes

          -  Has no history of androgen deprivation therapy within the past 6 months or has been
             treated neoadjuvantly up to 6 months prior to radical prostatectomy with the following
             agents; luteinizing hormone-releasing hormone (LHRH) agonists, anti-androgens, 5
             alpha-reductase inhibitors, and peripheral anti-androgens

          -  REGISTRATION:

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2; or
             Karnofsky performance of &gt; 60%

          -  Patients with any one of the following &quot;high risk&quot; criteria:

               -  Gleason, prostate specific antigen, seminal vesicle and margin status (GPSM)
                  score &gt;= 10 [GS + 1*(PSA 4-10)+2*(PSA 10.1-20)+3*(PSA &gt; 20)+2*(seminal vesicular
                  or nodal involvement) +2*(margin)](determined post radical prostatectomy)

               -  Post prostatectomy seminal vesicle invasion (pT3b) or pT4

               -  Two or less microscopic lymph nodal metastasis determined at the time of
                  prostatectomy OR

               -  Gleason 4+3 at the time of prostatectomy with margin positivity

          -  Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =&lt; 2 x
             institutional upper limit of normal (ULN)

          -  Total bilirubin =&lt; 2 x institutional ULN

          -  For patients identified as high-risk on the basis of pathological criteria after
             undergoing radical prostatectomy: interval time for study enrollment after radical
             prostatectomy will be =&lt; 28 days of the prostatectomy

          -  For patients identified as high-risk prior to undergoing radical prostatectomy:
             patients presenting with a high Gleason score (8-10) and/or a PSA &gt; 20 ng/ml are
             deemed eligible for study participation and study registration as long as the
             eligibility criteria is reconfirmed post radical prostatectomy; these patient groups
             may choose to register prior to or after prostatectomy

          -  Study randomization must occur =&lt; 28 days of radical prostatectomy; all patients
             consented on the trial, whether consented in the pre-prostatectomy or
             post-prostatectomy period, will be randomized to study treatments =&lt; 28 days of
             prostatectomy

          -  Ability to complete questionnaire(s) by themselves or with assistance

        Exclusion Criteria:

          -  PRE-REGISTRATION

          -  Transitional cell, small cell, or squamous cell carcinoma of the prostate; NOTE:
             patients consented for participation prior to prostatectomy, if detected to have above
             listed histo-pathologies after prostatectomy will be deemed ineligible and not proceed
             to study randomization

          -  History of primary prostate cancer treatment

          -  Evidence of clinical nodal disease (N1) or grossly evident metastasis at the time of
             enrollment

          -  History of bilateral orchiectomy; unilateral orchiectomy with normal range serum
             testosterone levels will be allowed for enrollment

          -  Evidence of metastasis on radiographic metastatic workup within a preceding period of
             4 months from the time of study entry, including whole body radionuclide bone scan,
             computed tomography (CT) and/or magnetic resonance (MR) scan of the pelvis and
             abdomen; otherwise will perform at the time of the baseline tests and result must be
             normal to continue on study; results of ProstaScint or other radionuclide scans,
             excluding radionuclide bone scans, will NOT be used to establish metastatic disease if
             all other studies are negative

          -  Receiving other experimental drugs =&lt; 4 weeks prior to consenting

          -  Uncontrolled infection

          -  History of other cancer, excluding squamous cell and basal cell skin cancers, within
             the preceding 2 years

          -  Documented history of human immunodeficiency virus (HIV) positivity or other acquired
             immunodeficiency disorder, congenital immunodeficiency disorder, or history of organ
             transplantation

          -  Unable to follow up every three months for the first year to Mayo Clinic, Rochester
             for receiving LHRH analogues or study monitoring

          -  REGISTRATION:

          -  Uncontrolled infection

          -  Unable to follow up every three months for the first year to Mayo Clinic, Rochester
             for receiving LHRH analogues or study monitoring
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Karnes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2009</study_first_submitted>
  <study_first_submitted_qc>July 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <results_first_submitted>October 8, 2013</results_first_submitted>
  <results_first_submitted_qc>October 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2013</results_first_posted>
  <last_update_submitted>December 11, 2015</last_update_submitted>
  <last_update_submitted_qc>December 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sixteen (16) participants were recruited at Mayo Clinic (Rochester) between July 2009 and June 2012.</recruitment_details>
      <pre_assignment_details>This trial was terminated early due to funding issues.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Androgen Deprivation Therapy</title>
          <description>Patients receive leuprolide acetate intramuscularly (IM) on day 1 OR goserelin acetate subcutaneously (SC) on day 1.</description>
        </group>
        <group group_id="P2">
          <title>No Androgen Deprivation Therapy</title>
          <description>Patients undergo observation every 3 months for 9 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Refused Further Treatment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Alternate Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Further Funding</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Androgen Deprivation Therapy</title>
          <description>Patients receive leuprolide acetate intramuscularly (IM) on day 1 OR goserelin acetate subcutaneously (SC) on day 1.</description>
        </group>
        <group group_id="B2">
          <title>No Androgen Deprivation Therapy</title>
          <description>Patients undergo observation every 3 months for 9 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="8.6"/>
                    <measurement group_id="B2" value="62.8" spread="7.4"/>
                    <measurement group_id="B3" value="62.0" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biochemical Progression-free Survival Rate</title>
        <time_frame>2 years</time_frame>
        <population>No participants reached the 2 years follow up due to the early termination of the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgen Deprivation Therapy</title>
            <description>Patients receive leuprolide acetate intramuscularly (IM) on day 1 OR goserelin acetate subcutaneously (SC) on day 1.</description>
          </group>
          <group group_id="O2">
            <title>No Androgen Deprivation Therapy</title>
            <description>Patients undergo observation every 3 months for 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Progression-free Survival Rate</title>
          <population>No participants reached the 2 years follow up due to the early termination of the trial.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Progression-free Survival (BPFS), Overall Survival (OS), and Prostate Cancer Specific Survival (PCS)</title>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity as Per NCI CTCAE Version 3</title>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Assessed by the FACT-P and LASA Tool Within and Between the Two Treatment Arms</title>
        <time_frame>Baseline and months 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurements of Serum and Urine Biomarkers, and Comparison Between the Two Arms</title>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Circulating Tumor Cells or Circulating Endothelial Cells Following Study Treatments With Biochemical Progression-free Survival Rate</title>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Prognostic and Predictive Tissue Based Biomarkers (CTCs, CECs)</title>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Androgen Deprivation Therapy</title>
          <description>Patients receive leuprolide acetate intramuscularly (IM) on day 1 OR goserelin acetate subcutaneously (SC) on day 1.</description>
        </group>
        <group group_id="E2">
          <title>No Androgen Deprivation Therapy</title>
          <description>Patients undergo observation every 3 months for 9 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="26" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" events="16" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="31" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" events="15" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gynecomastia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="21" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. R. Jeffrey Karnes</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507 284-4430</phone>
      <email>Karnes.R@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

